Genmab — September 2020

[Bulder]

Det her er kun begyndelsen på tiso. Der er større forventninger til andre kræftformer. F,eks, bugspytkirtlen, hvor præklinikken så god ud. Desuden vil der komme kombinationsbehandlinger.

[bikube]

Det eneste jeg har, der ikke er rødt i dag er mine Bear Tesla.

[GeorgeBest]

.@rcoledude presents results from the InnovaTV trial of tisotumab vedotin. There was a 24% response rate in patients w/ recurrent #cervical cancer, >50% of patients had stable disease beyond 6 months! https://twitter.com/shannonwestin/status/1308062372075122688?s=21

[Solsen]

https://twitter.com/seattlegenetics/status/1308048587255771136?s=21 Annonce på Twitter siger 13.800+ nye cervical patienter i US årligt. Så stort marked og de har vel også åbnet for at tiso kunne blive blockbuster. Vi har vel heller ikke set weekly behandling, som forventes med bedre resultat.

[E_L]

and Europe is a multiple of that, i think 3 or 4 times as much. we had an article here about it , but can't remember where

[E_L]

the real drama is offcourse in developing countries. a few hundred thousand....

[E_L]

maybe it was in the annual report

[Solsen]

Many i Japan...

[GeorgeBest]

Yes, Japan is very important, they don‘t give their teenage girls the hpv vaccine

[peter12]

On the latest fireside session JvdW said that Europe would require larger trials for TV

[Sukkeralf]

https://endpts.com/esmo20-seattle-genetics-eyes-4th-approval-with-new-data-in-a-crowded-field/

[Helge_LarsenPI-redaktør]

God morgen.

[transalp]

Go morgen..

[bibob]

God morgen.

[bibob]

Tisotumab på ESMO. https://www.onclive.com/view/tisotumab-vedotin-elicits-encouraging-responses-in-recurrent-metastatic-cervical-cancer?utm_source=sfmc&utm_medium=email&utm_campaign=9-21-20-_IMM-20-OGD0777_OncLiveSS_ESMO GLOBAL Conference Coverage eNews_Immunomedics_Trodelv&eKey=

[E_L]

same guy at youtube https://www.youtube.com/watch?v=ytGEecu6vrU

[E_L]

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS https://www.youtube.com/watch?v=Uz7OUaCIyfU

[E_L]

Tisotumab data sets Seattle Genetics up for another approval, says Piper Sandler Piper Sandler analyst Joseph Catanzaro maintained a Neutral rating and $172 price target on SGen following the company's data from tisotumab's Phase II study in previously treated recurrent/metastatic cervical cancer at ESMO, which the analyst noted were "consistent with June's topline release." Catanzaro believes this data sets the company up for an "accelerated approval path in this setting for tisotumab."

[Helge_LarsenPI-redaktør]

Great. Thanks E L.

[Mogan]

God morgen